Arrowhead Pharmaceuticals Company Insiders

ARWR Stock  USD 14.51  0.99  6.39%   
Arrowhead Pharmaceuticals' insiders are aggressively selling. The analysis of the overall insider sentiment regarding Arrowhead Pharmaceuticals suggests that virtually all insiders are panicking. Arrowhead Pharmaceuticals employs about 609 people. The company is managed by 14 executives with a total tenure of roughly 33 years, averaging almost 2.0 years of service per executive, having 43.5 employees per reported executive.
Christopher Anzalone  CEO
CEO and President Director, CEO of Calando, CEO of Tego, CEO of Nantope, CEO of Leonardo and CEO of Ablaris Therapeutics

Insider Sentiment 0

 Mostly Selling

 
Selling
 
Buying

Latest Trades

2025-03-13Christopher Richard AnzaloneDisposed 51425 @ 15.07View
2025-03-04Christopher Richard AnzaloneDisposed 133333 @ 17.02View
2025-01-23Adeoye Y OlukotunDisposed 959 @ 21View
2025-01-06Patrick O'brienDisposed 29184 @ 19.82View
2025-01-02Christopher Richard AnzaloneDisposed 11520 @ 19.05View
2024-12-27Adeoye Y OlukotunDisposed 2850 @ 20View
2024-12-23Christopher Richard AnzaloneDisposed 12563 @ 19.59View
2024-12-18Christopher Richard AnzaloneDisposed 26712 @ 21.24View
2024-12-16William D WaddillDisposed 3748 @ 21.9View
2024-07-02Tracie OliverDisposed 9394 @ 25.28View
2024-05-02Victoria VakienerDisposed 1799 @ 23.31View
Monitoring Arrowhead Pharmaceuticals' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
  
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Arrowhead Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in housing.
To learn how to invest in Arrowhead Stock, please use our How to Invest in Arrowhead Pharmaceuticals guide.

Arrowhead Pharmaceuticals' Workforce Through the Years

Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Arrowhead Pharmaceuticals' future performance. Based on our forecasts, it is anticipated that Arrowhead will maintain a workforce of slightly above 610 employees by April 2025.
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid

Arrowhead Pharmaceuticals Management Team Effectiveness

The company has return on total asset (ROA) of (0.4771) % which means that it has lost $0.4771 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (5.6533) %, meaning that it created substantial loss on money invested by shareholders. Arrowhead Pharmaceuticals' management efficiency ratios could be used to measure how well Arrowhead Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. As of 03/25/2025, Return On Tangible Assets is likely to drop to -0.5. In addition to that, Return On Capital Employed is likely to drop to -0.7. At this time, Arrowhead Pharmaceuticals' Total Assets are relatively stable compared to the past year. As of 03/25/2025, Non Current Assets Total is likely to grow to about 536.5 M, while Net Tangible Assets are likely to drop slightly above 202.9 M.
As of 03/25/2025, Common Stock Shares Outstanding is likely to grow to about 144.6 M, though Net Loss is likely to grow to (175.5 M).

Arrowhead Pharmaceuticals Workforce Comparison

Arrowhead Pharmaceuticals is rated below average in number of employees category among its peers. The total workforce of Health Care industry is presently estimated at about 10,885. Arrowhead Pharmaceuticals holds roughly 609 in number of employees claiming about 6% of equities under Health Care industry.

Arrowhead Pharmaceuticals Insider Trading History

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Arrowhead Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Arrowhead Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Arrowhead Pharmaceuticals insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Buy/Sell Ratio# Purchases Trades# Sales TradesTotal Shares PurchasedTotal Shares Sold
2025-03-01
0.4667
7
15
 647,946 
 727,559 
2024-12-01
0.7
7
10
 200,398 
 64,161 
2024-03-01
0.2308
9
39
 445,499 
 283,716 
2023-12-01
1.5
6
4
 89,922 
 56,038 
2023-09-01
0.5
2
4
 115,310 
 68,230 
2023-06-01
0.25
2
8
 104,928 
 234,356 
2023-03-01
0.7917
19
24
 332,720 
 73,830 
2022-12-01
0.75
3
4
 284,400 
 82,125 
2022-09-01
0.2
1
5
 2,501 
 596,823 
2022-03-01
0.325
13
40
 1,177,994 
 424,757 
2021-12-01
0.2
3
15
 40,461 
 188,361 
2021-03-01
0.3929
11
28
 1,114,500 
 328,913 
2020-12-01
0.25
10
40
 213,847 
 561,904 
2020-09-01
0.3333
1
3
 50,000 
 100,000 
2020-06-01
0.4615
18
39
 98,653 
 414,581 
2020-03-01
1.0
22
22
 1,449,867 
 187,347 
2019-12-01
0.1071
3
28
 106,858 
 601,066 
2019-09-01
0.3
3
10
 112,650 
 408,545 
2019-06-01
0.5
4
8
 84,448 
 209,275 
2019-03-01
0.6216
23
37
 2,024,429 
 1,257,458 
2018-12-01
0.3636
4
11
 134,596 
 533,644 
2018-09-01
0.3333
2
6
 45,000 
 254,834 
2018-06-01
0.5
4
8
 54,000 
 131,600 
2018-03-01
1.0
10
10
 980,000 
 414,208 
2016-09-01
0.6667
4
6
 40,000 
 53,800 
2016-06-01
2.0
2
1
 24,289 
 15,772 
2016-03-01
1.7143
12
7
 1,205,000 
 115,218 
2015-03-01
4.0
12
3
 1,200,000 
 115,000 
2014-12-01
1.25
5
4
 154,500 
 52,500 
2014-09-01
0.5556
5
9
 62,000 
 124,000 
2014-06-01
0.6667
2
3
 22,000 
 44,000 
2014-03-01
1.6
16
10
 786,000 
 175,148 
2013-12-01
3.0
3
1
 3,500 
 28,000 
2013-09-01
3.5
7
2
 157,991 
 40,000 
2013-06-01
6.0
6
1
 475,000 
 105,000 
2013-03-01
0.6667
4
6
 65,000 
 110,000 
2012-09-01
0.6
3
5
 100,000 
 75,000 
2012-03-01
0.4286
3
7
 363,000 
 227,000 
2010-09-01
2.5
5
2
 655,000 
 200,000 
2010-03-01
5.0
5
1
 1,003,250 
 10,000 
2008-09-01
2.0
2
1
 328,000 
 54,688 
2008-06-01
2.0
4
2
 175,000 
 2,100,000 
2007-03-01
0.2727
6
22
 437,000 
 1,451,572 
2005-12-01
0.5
1
2
 750,000 
 25,000 
2005-06-01
1.75
14
8
 2,925,063 
 1,459,242 
2005-03-01
0.3333
1
3
 25,000 
 60,000 
2004-12-01
0.8
4
5
 40,000 
 136,000 
2004-03-01
0.2727
3
11
 350,000 
 1,344,487 

Arrowhead Pharmaceuticals Notable Stakeholders

An Arrowhead Pharmaceuticals stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Arrowhead Pharmaceuticals often face trade-offs trying to please all of them. Arrowhead Pharmaceuticals' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Arrowhead Pharmaceuticals' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Christopher AnzaloneCEO and President Director, CEO of Calando, CEO of Tego, CEO of Nantope, CEO of Leonardo and CEO of Ablaris TherapeuticsProfile
Nadia MBAVP TreasurerProfile
CPA CPAChief OfficerProfile
Kenneth MyszkowskiChief OfficerProfile
Javier MDChief OfficerProfile
Bruce MDChief ScientistProfile
Vincent CFAHead VPProfile
MBA MDChief MedicineProfile
Tracie OliverChief OfficerProfile
Aaron TanHead TaxProfile
PharmD JDCOO CounselProfile
Howard LovyDirector CommunicationsProfile
Mark DavisFounder CalandoProfile
Mark SeefeldHead VPProfile

About Arrowhead Pharmaceuticals Management Performance

The success or failure of an entity such as Arrowhead Pharmaceuticals often depends on how effective the management is. Arrowhead Pharmaceuticals management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Arrowhead management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Arrowhead management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last ReportedProjected for Next Year
Return On Tangible Assets(0.48)(0.50)
Return On Capital Employed(0.67)(0.70)
Return On Assets(0.47)(0.50)
Return On Equity(3.72)(3.53)

Arrowhead Pharmaceuticals Workforce Analysis

Traditionally, organizations such as Arrowhead Pharmaceuticals use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Arrowhead Pharmaceuticals within its industry.

Arrowhead Pharmaceuticals Manpower Efficiency

Return on Arrowhead Pharmaceuticals Manpower

Revenue Per Employee5.8K
Revenue Per Executive253.6K
Net Loss Per Employee1M
Net Loss Per Executive43.5M
Working Capital Per Employee972.6K
Working Capital Per Executive42.3M

Additional Tools for Arrowhead Stock Analysis

When running Arrowhead Pharmaceuticals' price analysis, check to measure Arrowhead Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arrowhead Pharmaceuticals is operating at the current time. Most of Arrowhead Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Arrowhead Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arrowhead Pharmaceuticals' price. Additionally, you may evaluate how the addition of Arrowhead Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.